Publicaciones en las que colabora con Francisco Ignacio Ga Bosa Ojeda (11)

2017

  1. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial

    Journal of Pineal Research, Vol. 62, Núm. 1

  2. Usefulness of Early Treatment With Melatonin to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention (From the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty Trial)

    American Journal of Cardiology, Vol. 120, Núm. 4, pp. 522-526

2014

  1. Change in growth differentiation factor 15, but not c-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome

    Mediators of Inflammation, Vol. 2014

  2. Measurement of glomerular filtration rate: Internal and external validations of the iohexol plasma clearance technique by HPLC

    Clinica Chimica Acta

2012

  1. Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: A pilot study

    International Journal of Cardiology, Vol. 158, Núm. 1, pp. 160-162

2010

  1. Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction

    American Journal of Cardiology, Vol. 106, Núm. 11, pp. 1540-1544

2009

  1. Angioplastia primaria y variaciones diurnas

    Revista Espanola de Cardiologia

  2. Cross-Talk Between Primary Percutaneous Coronary Intervention, Arterial Inflammation, and Light/Dark Patterns

    JACC: Cardiovascular Interventions

  3. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-Effects on soluble CD40 ligand concentrations

    Atherosclerosis, Vol. 206, Núm. 2, pp. 523-527

  4. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the i f current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale

    Cardiovascular Drugs and Therapy, Vol. 23, Núm. 3, pp. 243-247

  5. Role of Myeloperoxidase as Predictor of Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

    American Journal of Cardiology, Vol. 104, Núm. 5, pp. 634-637